Carcinoid heart disease: An update

Scandinavian Journal of Gastroenterology, Supplement

Volumn 37, Issue 236, 2002, Pages 66-71

  Quaedvlieg, P F H J ^a   Lamers, C B H W ^a   Taal, B G ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Carcinoid; Carcinoid heart disease; Epidemiology; Histology; Neuroendocrine; Review; Treatment

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 5 HYDROXYINDOLEACETIC ACID; ALPHA INTERFERON; HORMONE; SOMATOSTATIN DERIVATIVE;

ARTIFICIAL EMBOLISM; CANCER STAGING; CANCER SURGERY; CARCINOID SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DISEASE COURSE; DRUG FORMULATION; DRUG RESPONSE; HEART DISEASE; HUMAN; INCIDENCE; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; LIVER METASTASIS; MEDICAL LITERATURE; METASTASIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; SURGICAL TECHNIQUE; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; WHEEZING; PATHOLOGY; REVIEW; SURVIVAL RATE;

CARCINOID HEART DISEASE; HUMANS; INCIDENCE; PALLIATIVE CARE; SURVIVAL RATE;

EID: 0035981664     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655202320621481     Document Type: Conference Paper

References (85)

1. Kloppel G, Heitz PU. Classification of normal and neoplastic neuroendocrine cells. Ann NY Acad Sci 1994;733:19-23.
2. Wilander E, Lundqvist M, el Salhy M. Serotonin in fore-gut carcinoids. A survey of 60 cases with regard to silver stains, formalin-induced fluorescence and serotonin immunocytochemistry. J Pathol 1985;145:251-8.
3. Wilander E. Diagnostic pathology of gastrointestinal and pancreatic neuroendocrine tumours. Acta Oncol 1989;28:363-9.
4. Wilander E, Scheibenpflug L, Eriksson B, Oberg K. Diagnostic criteria of classical carcinoids. Acta Oncol 1991;30:469-75.
5. Modlin IM, Basson MD. Clinical applications of gastrointestinal hormones. Endocrinol Metab Clin North Am 1993;22:823-44.
6. Williams ED, Sanders M. The classification of carcinoid tumours. Lancet 1963;1:238.
7. Travis WD, Colby TV, Brambilla E. WHO international histological classification of tumors: histologic typing of lung and pleural tumours, 3rd ed. Berlin: Springer-Verlag; 1999.
8. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-60.
9. Crocetti E, Buiatti E, Amorosi A. Epidemiology of carcinoid tumours in central Italy. Eur J Epidemiol 1997;13:357-9.
10. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-829.
11. Godwin JD. Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975;36:560-9.
12. Chow JS, Chen CC, Ahsan H, Neugut AI. A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990. Int J Epidemiol 1996;25:722-8.
13. Westergaard T, Frisch M, Melbye M. Carcinoid tumors in Denmark 1978-1989 and the risk of subsequent cancers. A population-based study. Cancer 1995;76:106-9.
14. Newton JN, Swerdlow AJ, Santos Silva I, Vessey MP, Grahame-Smith DG, Primatesta P, et al. The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 1994;70:939-42.
15. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands: an epidemiological study with 2391 patients. Ann Oncol 2001;12:1295-300.
16. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-96.
17. Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 1988;77:264-9.
18. Himelman RB, Schiller NB. Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. Am J Cardiol 1989;63:347-52.
19. Denney WD, Kemp WE Jr, Anthony LB, Oates JA, Byrd BF, III. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol 1998;32:1017-22.
20. Moyssakis IE, Rallidis LS, Guida GF, Nihoyannopoulos PI. Incidence and evolution of carcinoid syndrome in the heart. J Heart Valve Dis 1997;6:625-30.
21. Dusmet M, McKneally MF. Bronchial and thymic carcinoid tumors: a review. Digestion 1994;55 Suppl 3:70-6.
22. Moertel CG, Dockerty MB, Judd ES. Carcinoid tumors of the vermiform appendix. Cancer 1968;21:270-8.
23. Federspiel BH, Burke AP, Sobin LH, Shekitka KM. Rectal and colonic carcinoids. A clinicopathologic study of 84 cases. Cancer 1990;65:135-40.
24. Jetmore AB, Ray JE, Gathright JB Jr, McMullen KM, Hicks TC, Timmcke AE. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 1992;35:717-25.
25. Jensen RT, Doherty GM. Cancer of the endocrine system: carcinoid tumors and the carcinoid syndrome. In: DeVita V, Hellman S, Rosenberg SA, editors. Principles and practice of oncology. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 1813-33.
26. Ferrans VJ, Roberts WC. The carcinoid endocardial plaque; an ultrastructural study. Hum Pathol 1976;7:387-409.
27. Muller HG. Siebenmann RE. Ultrastructure of endocardial lesions in the carcinoid syndrome. Virchows Arch A Pathol Anat Histol 1981;391:33-44.
28. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81.
29. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
30. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-5.
31. Norheim I, Oberg K, Theodorsson-Norheim E, Lindgren PG, Lundqvist G, Magnusson A, et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987;206:115-25.
32. Ross EM, Roberts WC. The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med 1985;79:339-54.
33. Roberts WC. A unique heart disease associated with a unique cancer: carcinoid heart disease. Am J Cardiol 1997;80:251-6.
34. Lundin L. Carcinoid heart disease. A cardiologist's viewpoint. Acta Oncol 1991;30:499-502.
35. Loftus JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumors. Adv Surg 1995;28:317-36.
36. Rothmund M, Kisker O. Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum. Digestion 1994;55 Suppl 3:86-91.
37. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1502-22.
38. Naunheim KS, Zeitels J, Kaplan EL, Sugimoto J, Shen KL, Lee CH, et al. Rectal carcinoid tumors: treatment and prognosis. Surgery 1983;94:670-6.
39. Andaker L, Lamke LO, Smeds S. Follow-up of 102 patients operated on for gastrointestinal carcinoid. Acta Chir Scand 1985;151:469-73.
40. Sauven P, Ridge JA, Quan SH, Sigurdson ER. Anorectal carcinoid tumors. Is aggressive surgery warranted? Ann Surg 1990;211:67-71.
41. Makridis C, Oberg K, Juhlin C, Rastad J, Johansson H, Lorelius LE, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990;14:377-83.
42. Thompson GB, van Heerden JA, Martin JK, Jr., Schutt AJ, Ilstrup DM, Carney JA. Carcinoid tumors of the gastrointestinal tract: presentation, management, and prognosis. Surgery 1985;98:1054-63.
43. Koura AN, Giacco GG, Curley SA, Skibber JM, Feig BW, Ellis LM. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 1997;79:1294-8.
44. Soga J. Carcinoids of the rectum: an evaluation of 1271 reported cases. Surg Today 1997;27:112-9.
45. Stefani A, Morandi U, Urgese AL, Rivasi F, Lodi R. Carcinoid tumors of the lung. An analysis of 65 operated cases. J Cardiovasc Surg (Torino) 1999;40:607-12.
46. Shah R, Sabanathan S, Mearns J, Richardson J, Goulden C. Carcinoid turnout of the lung. J Cardiovasc Surg (Torino) 1997;38:187-9.
47. Schreurs AJ, Westermann CJ, van den Bosch JM, Vanderschueten RG, de la Riviere B, Knaepen PJ. A twenty-five-year follow-up of ninety-three resected typical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1992;104:1470-5.
48. Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996;39:279-83.
49. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38:430-8.
50. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996;77:402-8.
51. Lamberts SW, Reubi JC, Krenning EP. The role of somatostatin analogs in the control of tumor growth. Semin Oncol 1994;21:61-4.
52. Kuin A, Aalders M, Lamfers M, van Zuidam DJ, Essers M, Beijnen JH, et al. Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor miodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). Br J Cancer 1999;79:793-801.
53. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours. Eur J Cancer 1996;32A:1924-32.
54. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994;21:561-81.
55. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996;14:1829-38.
56. Grander D, Sangfelt O, Erickson S. How does interferon exert its cell growth inhibitory effect? Eur J Haematol 1997;59:129-35.
57. Detjen KM, Welzel M, Farwig K, Brembeck FH, Kaiser A, Riecken EO, et al. Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 2000;118:735-48.
58. Veenhof CH, de Wit R, Taal BG, Dirix LY, Wagstaff J, Hensen A, et al. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour. Eur J Cancer 1992;28:75-8.
59. Biesma B, Willemse PH, Mulder NH, Verschueren RC, Kema IP, de Bruijn HW, et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on turnouts and tumour markers. Br J Cancer 1992;66:850-5.
60. Oberg K. The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin North Am 1993;22:941-52.
61. Rougier P, Ducreux M. Systemic chemotherapy of advanced digestive neuroendocrine tumours. Ital J Gastroenterol Hepatol 1999;31 Suppl 2:S202-6.
62. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
63. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D, Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23.
64. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94:1381-7.
65. Oberg K, Eriksson B, Janson ET. The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Ann NY Acad Sci 1994;733:471-8.
66. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225-9.
67. Tiensuu Janson EM, Ahlstrom H, Andersson T, Oberg KE. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992;28A:1647-50.
68. Hanssen LE, Schrumpf E, Kolbenstvedt AN, Tausjo J, Dolva LO. Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 1989;24:787-95.
69. Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997;225:355-64.
70. Lang H, Oldhafer KJ, Weimann A, Schlitt HJ, Scheumann GF, Flemming P, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225:347-54.
71. Bechstein WO, Neuhaus P. Liver transplantation for hepatic metastases of neuroendocrine tumors. Ann NY Acad Sci 1994;733:507-14.
72. Schupak KD, Wallner KE. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int J Radiat Oncol Biol Phys 1991;20:489-95.
73. Wangberg B, Westberg G, Tylen U, Tisell L, Jansson S, Nilsson O, et al. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 1996;20:892-9.
74. Moertel CG, Johnson CM, McKusick MA, Martin JK Jr, Nagorney DM, Kvols LK, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-9.
75. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293-301.
76. Marlink RG, Lokich JJ, Robins JR, Clouse ME. Hepatic arterial embolization for metastatic hormone-secreting tumors. Technique, effectiveness, and complications. Cancer 1990;65:2227-32.
77. Nobin A, Mansson B, Lunderquist A. Evaluation of temporary liver dearterialization and embolization in patients with metastatic carcinoid tumour. Acta Oncol 1989;28:419-24.
78. Kim YH, Ajani JA, Carrasco CH, Dumas P, Richli W, Lawrence D, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999;17:474-8.
79. Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, et al. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. Am J Roentgenol 1998;170:339-44.
80. Drougas JG, Anthony LB, Blair TK, Lopez RR, Wright JK Jr, Chapman WC, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998;175:408-12.
81. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993;71:2624-30.
82. Stokes KR, Stuart K, Clouse ME. Hepatic arterial chemoembolization for metastatic endocrine tumors. J Vasc Interv Radiol 1993;4:341-5.
83. Therasse E, Breittmayer F, Roche A, De Baere T, Indushekar S, Ducreux M, et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993;189:541-7.
84. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994;116:1111-6.
85. Diaco DS, Hajarizadeh H, Mueller CR, Fletcher WS, Pommier RF, Woltering EA. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg 1995;169:523-8.